A recent study reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional lifestyle plans.
Published data in a major medical journal shows that while overweight individuals can lose substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these medications should be informed of the risk of quick rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of regain implies a return to starting mass within about a year and a half.
Weighing Therapies
The study, which looked at 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through dieting generally have a slower creep back—perhaps 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors believe the way of the injections explains the amplified regain.
These medications imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals contend that, due to the high risk of relapse, the therapy should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," similar to managing diseases like hypertension.
Patient Accounts
People who have come off the jabs report a powerful resurgence of hunger.
"I experienced a switch that goes on and I was suddenly extremely hungry," recalled an individual.
This challenge is compounded if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Growing Adoption
Recent estimates indicate that millions of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Finally, experts stress that while these medications are potent agents for weight loss, they are not a standalone cure and long-term success likely depends on ongoing behavioural support.
